|By Marketwired .||
|June 16, 2014 09:30 AM EDT||
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/16/14 -- VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue and regenerative medicine, today announces that the Canadian Intellectual Property Office has issued a Notice of Allowance for Canadian patent No. 2,684,022, entitled "Mesoderm and Definitive Endoderm Cell Populations." This patent, which is licensed exclusively to VistaGen by the Icahn School of Medicine at Mount Sinai in New York, will expand VistaGen's intellectual property portfolio for pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.
"This important Canadian patent allowance extends our core intellectual property protection in a market that has been strategically significant to us for many years," stated Shawn K. Singh, JD, VistaGen's chief executive officer. "In a manner similar to our recently announced Notice of Allowance for its counterpart, U.S. Patent Application 12/836,275, this new Canadian patent allowance and our world-class differentiation and assay formulation expertise put us in a strong position to pursue additional stem cell research projects in Canada, especially innovative projects involving liver biology, customized drug metabolism assays, and pilot nonclinical studies using pancreatic beta-islet cells for drug and regenerative cell therapies for diabetes."
About VistaGen Therapeutics
VistaGen, a stem cell company headquartered in South San Francisco, California, is focused on drug rescue and regenerative medicine. We believe better cells lead to better medicines and that the key to making better cells is precisely controlling the differentiation of human pluripotent stem cells, which are the building blocks of all cells of the human body. For over 15 years, our stem cell research and development teams and collaborators have developed proprietary methods for controlling the differentiation of human pluripotent stem cells and the production and maturation of numerous specific types of adult human cells. Our drug rescue activities are focused on combining our stem cell technology and assay development expertise with medicinal chemistry to generate Drug Rescue Variants. These are novel, proprietary and safer chemical variants of once-promising small molecule drug candidates discovered and developed by pharmaceutical or biotechnology companies, the U.S. National Institutes of Health, or academic laboratories, which have positive efficacy data supporting their therapeutic and commercial potential, but have been discontinued due to unexpected heart or liver safety concerns.
With $8.8 million of grant funding awarded from the U.S. National Institutes of Health, VistaGen has successfully completed Phase 1 development of AV-101, an orally available, non-sedating, small molecule prodrug candidate. AV-101 is aimed at the multi-billion dollar neurological disease and disorders market, including neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, epilepsy and depression and Parkinson's disease. Our AV-101 IND application on file at the FDA covers clinical development for neuropathic pain.
Cautionary Statement Regarding Forward-Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen's drug and regenerative medicine research, discovery, development and rescue activities, its ability to enter into strategic licensing and partnering arrangements, risks and uncertainties relating to its protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the foregoing activities. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.
Dec. 11, 2016 12:00 AM EST Reads: 1,111
Dec. 11, 2016 12:00 AM EST Reads: 2,393
Dec. 11, 2016 12:00 AM EST Reads: 909
Dec. 10, 2016 11:45 PM EST Reads: 1,796
Dec. 10, 2016 11:15 PM EST Reads: 1,219
Dec. 10, 2016 10:15 PM EST Reads: 2,073
Dec. 10, 2016 09:15 PM EST Reads: 1,355
Dec. 10, 2016 07:30 PM EST Reads: 1,822
Dec. 10, 2016 07:00 PM EST Reads: 4,159
Dec. 10, 2016 06:30 PM EST Reads: 1,973
Dec. 10, 2016 06:30 PM EST Reads: 1,551
Dec. 10, 2016 06:30 PM EST Reads: 1,036
Dec. 10, 2016 06:15 PM EST Reads: 1,099
"ReadyTalk is an audio and web video conferencing provider. We've really come to embrace WebRTC as the platform for our future of technology," explained Dan Cunningham, CTO of ReadyTalk, in this SYS-CON.tv interview at WebRTC Summit at 19th Cloud Expo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 10, 2016 05:30 PM EST Reads: 1,012
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Dec. 10, 2016 05:15 PM EST Reads: 1,428